MS
ARQT icon

Maven Securities’s Arcutis Biotherapeutics ARQT Stock Holding History

Maven Securities’s Portfolio ARQT Stock Details ARQT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-116,728
Closed -$3.29M – 1051
2021
Q1 		$3.29M Buy
+116,728
New +$3.64M 0.15% 134
2020
Q4 		– Sell
-15,000
Closed -$433K – 569
2020
Q3 		$433K Buy
+15,000
New +$401K 0.04% 412

Other funds holding ARQT

FM
Frazier Management Seattle, Washington $1.12M AUM 151.58% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

Maven Securities's ARQT Position: Q2 2021 in Review

Maven Securities sold out of Arcutis Biotherapeutics (ARQT) in Q2 2021, closing a stake of 116,728 shares — an estimated $3.29M sold.

Maven Securities first reported a position in ARQT in Q3 2020 and held it in 2 quarters. The position peaked at $3.29M in Q1 2021. 102 funds tracked by Wall St. Rank hold ARQT as of Q2 2021.

  • Maven Securities reported no remaining Arcutis Biotherapeutics position as of Q2 2021 after selling out during the quarter.
  • Maven Securities sold 116,728 Arcutis Biotherapeutics shares in Q2 2021, an estimated $3.29M.
  • Maven Securities first reported a position in Arcutis Biotherapeutics in Q3 2020 and held it in 2 quarters.
  • Maven Securities's Arcutis Biotherapeutics position peaked at $3.29M in Q1 2021.
  • 102 funds tracked by Wall St. Rank held Arcutis Biotherapeutics as of Q2 2021.

Based on Maven Securities's 13F filing for Q2 2021, filed 16 Aug 2021.